No human medicinal product can be imported, sold, or marketed in Saudi Arabia without a marketing authorization from the Saudi Food and Drug Authority (SFDA). SFDA drug registration — the pathway for pharmaceutical and medicinal product registration in Saudi Arabia — is a structured, fully electronic process — an eCTD dossier submitted through the Saudi Drug Registration (SDR) platform, reviewed against the SFDA Regulatory Framework for Drugs Approval — and how well you prepare the dossier and the pricing file largely determines whether you approve in months or lose a year to deficiency letters.
Who can submit an SFDA drug registration application?
Foreign pharmaceutical manufacturers cannot deal with the SFDA directly. Registration applications must be submitted through an entity established in Saudi Arabia — a local authorized agent or scientific office that holds the appropriate SFDA licensing and manages the submission, authority correspondence, and post-marketing obligations on the manufacturer's behalf.
Choosing this local partner is a strategic decision, not an administrative one. An independent regulatory partner keeps your registrations under your control: you can appoint, add, or change commercial distributors freely without your marketing authorization being tied to any one of them.
The registration pathway, step by step
The SFDA drug registration process follows a defined sequence. In practice it looks like this:
- Product classification and eligibility — confirm the product is a drug (not a health/herbal product with its own rules) and identify the pathway: new chemical entity, generic, or biologic.
- eCTD dossier preparation — compile CTD Modules 1–5 in eCTD format, including Saudi-specific Module 1 requirements.
- SDR platform submission — file through the SFDA's electronic drug registration system via your local agent, with administrative screening before the technical review begins.
- Technical and scientific review — respond to deficiency letters and CMC, safety, and efficacy queries within the deadlines set by the SFDA.
- Pricing review — the SFDA pricing committee assesses the proposed price against its published pricing rules before the marketing authorization is granted.
- Marketing authorization — once quality, safety, efficacy, and pricing are cleared, the SFDA issues the registration and the product can be legally marketed in the Kingdom.
The eCTD dossier: what the SFDA expects
The SFDA accepts submissions only in eCTD format, and dossier completeness is the single biggest factor in how fast a file moves. The core documents include:
- Certificate of Pharmaceutical Product (CPP) from the reference regulatory authority.
- GMP certificates and manufacturing site details for every site in the supply chain.
- Stability studies covering the conditions required for the Saudi market.
- Bioequivalence studies for generics, conducted to SFDA-acceptable standards.
- Summary of Product Characteristics (SmPC), patient leaflet, and Arabic/English labeling.
- Pricing application with the certificate of pricing in the country of origin and reference markets.
How long does SFDA drug registration take?
The SFDA publishes target review timelines in working days: around 155 working days for a standard generic (93 under priority review) and around 280 working days for a new drug already registered with a reference regulatory authority (168 under priority review).
In practice, companies should plan for roughly 6–12 months end to end depending on product type, dossier quality, and how quickly deficiency responses are returned. Clock stops during response periods are where most timelines slip — a pre-submission gap analysis is the cheapest way to protect the schedule.
Qualifying products — for example those addressing unmet medical needs — can apply for the SFDA's priority review pathway, which cuts published timelines by roughly 40 percent.
After approval: lifecycle obligations
Registration is not the finish line. Marketing authorization holders must maintain the registration through variation submissions for any change to the product, renewals before expiry, and ongoing pharmacovigilance — including periodic safety update reports (PSUR/PBRER) and adverse event reporting to the SFDA.
Labeling and SmPC updates must track SFDA guideline changes, and the local agent remains the authority's contact point for inspections, queries, and safety communications throughout the product's life on the Saudi market.
How MRG supports your SFDA drug registration
MRG has operated in Riyadh since 2012 and holds SFDA Consultation Office license CO-2023-FO-0022 covering pharmaceutical, medical device, and cosmetic activities. Our pharmaceutical team manages the full registration lifecycle: pathway assessment, eCTD dossier compilation and gap analysis, SDR submission, deficiency responses, pricing strategy, and post-approval variations, renewals, and pharmacovigilance.
With offices in Saudi Arabia, the UAE, and Egypt, we support manufacturers entering the wider MENA region through a single regulatory partner. If you are planning drug registration in Saudi Arabia, talk to our consultants about your product's pathway and timeline.
